Trump warns Democrats Obamacare will die without cash infusion | | WASHINGTON (Reuters) - U.S. President Donald Trump warned Democrats on Sunday that Obamacare was in trouble and would die without government funding, apparently referring to the possibility of ending federal subsidies to help lower-income people buy health insurance. |
| |
Becton Dickinson to acquire Bard for $24 billion | | NEW YORK (Reuters) - U.S. medical equipment supplier Becton Dickinson and Co will acquire C R Bard Inc, in a $24 billion cash-and-stock deal, adding Bard's devices to its portfolio in the high-growth sectors of oncology and surgery, both companies said on Sunday. |
| |
Bristol-Myers NASH drug reduces liver fat in midstage study | | (Reuters) - Bristol-Myers Squibb Co said its lead experimental drug for nonalcoholic steatohepatitis, or NASH, significantly reduced liver fat versus placebo, according to data from a mid-stage trial presented at a medical meeting on Saturday. |
| |
Uphill battle looms as Trump seeks revamped healthcare plan | | WASHINGTON (Reuters) - President Donald Trump, striving to make good on a top campaign promise, is pushing his fellow Republicans who control Congress to pass revamped healthcare legislation but the same intraparty squabbling that torpedoed it last month could do it again. |
| |
FDA approves Samsung Bioepis' copy of J&J's Remicade: company | | SEOUL (Reuters) - South Korea's Samsung Bioepis Co Ltd said on Saturday the U.S. Food and Drug Administration approved its copy of Johnson & Johnson's rheumatoid arthritis drug Remicade, the first drug developed by the Samsung Group unit approved in the United States. |
| |
Valeant prices psoriasis treatment at $3,500 per month | | (Reuters) - Canadian drugmaker Valeant Pharmaceuticals International Inc said it had priced its recently approved plaque psoriasis treatment at $3,500 per month, ahead of an expected U.S. launch in the second half of 2017. |
| |
| | |